The Totally Civil Covid Thread.

  • University of Alabama at Birmingham Study--Four-Fold Reduction in CD34+ Cells Among COVID-19 Vaccinated: A Threat to Future Regenerative Therapies?

    University of Alabama at Birmingham Study--Four-Fold Reduction in CD34+ Cells Among COVID-19 Vaccinated: A Threat to Future Regenerative Therapies?
    Scientists affiliated with Microbiology, Pathology, and School of Medicine at the University of Alabama at Birmingham led an investigation into the impact…
    www.trialsitenews.com


    Scientists affiliated with Microbiology, Pathology, and School of Medicine at the University of Alabama at Birmingham led an investigation into the impact of previous SARS-CoV-2 infection, specifically asymptomatic or undocumented infection as well as COVID-19 vaccination on CD34+ hematopoietic stem cell progenitor cells (HSPCs) in Umbilical Cord Blood (UBC). They utilized 111 UCB donor samples from the University of Alabama at Birmingham that met study eligibility criteria and thus subjected to a series of tests. The study authors, led by corresponding author Masakazu Kamata, report observing “striking changes” in the CD34+ cell fraction. Finding that the “total numbers of CD34+ cells drastically reduced 4-fold in the vaccinated donor group,” the study authors report a correlate with the “induction of apoptosis in CD34+ cells, likely mediated by IFN-y-related pathways as determined by total transcriptome assay.” Moreover, two different hematopoiesis tests demonstrated skewed hematopoietic abilities of the subject CD34+ cells including A) an in vitro colony formation unit (CFU) and B) mouse humanization assays evidenced by high T cell/B cell ratios plus higher erythrocyte & lower granulocyte-macrophage colony formations. The authors of this yet to be peer reviewed study suggest that “both previous SARS-CoV-2 infection and/or vaccination impair CD34+ HSPCs quantitatively and qualitatively by stress-induced hematopoiesis, which is the production of blood cells and platelets. These findings, according to the study authors, raises “a great concern in the collection as well as the utilization of UCB as a source of CD34+ HSPCs used in/for future therapies, treatments and research.”


    What are HSPCs and why is this study important?

    As the study authors point out at the onset, umbilical cord blood or “UCB” represents an “irreplaceable source of hematopoietic stem cell progenitor cells (HSPCs). A rare population of precursor cells, HSPCs possess the capacity for self-renewal and multilineage differentiation. In the bone marrow, HSPCs warrant blood cell homeostasis.


    UCB blood originates from the neonate… and differs from that of adult peripheral blood, in which UCB contains higher numbers of monocytes and nucleated red blood cells (RBCs), and lower numbers of matured RBCs and T cells, especially CD8+ T cells.


    The authors point out, “Lymphocytes in UCB produce fewer absolute levels of cytokines and have higher abundance of anti-inflammatory cytokines than adult peripheral blood sources.” Importantly, “UCB is highly enriched with multipotent hematopoietic stem progenitor cells (HSPCs) as identified by the surface expression ofCD34 molecules, which are essential for the maintenance of the bone marrow and blood systems.”


    Present in blood and bone marrow, these cells are capable of forming mature blood cells---like the red blood cells that carry oxygen---platelets (cells that stop bleeding) and white blood cells (cells that fight infections).


    HSPCs represent a fundamentally important contributor to the regenerative therapy revolution. Although they have been employed for over five decades now in hematological transplantations, they are typically isolated from mobilized peripheral blood or umbilical cord blood. As reported by scientists at the Stem Cell Institute at James Graham Brown Cancer Center, University of Louisville, “The successful clinical application of HSPCs is widely understood to have helped establish the rationale for the development of stem cell therapies and regenerative medicine.”


    The team reported that “HSPCs have been widely used for various therapeutic and research purposes, such as bone marrow transplants, and the treatment of severe cases of COVID-19.” Whereas the fate and functionality of CD34+ HSPCs are severely affected by the host’s health status, such as infection by a pathogen, and can cause stress-induced hematopoiesis in these HSPCs.”


    Kamata and team report that presently, “the effects of SARS-CoV-2 infection and COVID-19 vaccination on UCB phenotype, specifically the HSPCs therein, are currently unknown.”


    The study

    In this study the Birmingham Alabama-led team tested the effects of both SARS-CoV-2 infection as well as COVID-19 vaccination on mother and the fate and functionalities of HSPCs in the UCB.


    Finding that “the numbers of frequencies of HSPCs in the UCB decreased significantly in donors with previous SARS-CoV-2 infection and more so with COVID-19 vaccination,” this occurred through the “induction of apoptosis” or the death of cells which occurs as a normal and controlled part of an organism’s growth or development. This observation, suggests the researchers, likely is “mediated by IFN-y-dependent pathways.”


    Designing two independent hematopoiesis (formation of new blood cells) assays including 1) a colony forming unit assay and 2) a mouse humanization assay, the study authors report the outcomes of the study…”revealed skewed hematopoiesis of HSPCs obtained from donors delivered from mothers with SARS-CoV2 infection history. These results indicate that SARS-CoV-2 infection and COVID-19 vaccination impair the functionalities and survivability of HSPCs in the UCB, which would raise unprecedented concerns on the future of HSPC-based therapies.”


    The cord blood samples for this study were made possible by doctors, midwives, nurses, and coordinators participating in the collection of cord blood samples at University of Alabama at Birmingham’s department of obstetrics & gynecology.


    A Discussion

    COVID-19 vaccines along with SARS-CoV-2, according to the study authors, significantly reduce CD34+ cell frequencies, thus lowering overall CD34+ cell numbers likely because of the induction of apoptosis or cell death.


    Importantly, COVID-19 vaccinated samples lead to a significantly greater reduction than SARS-CoV-2 infection. Interestingly, the CD34+ reduction in both cell numbers of frequency correlates with the timing of the second COVID-19 vaccination of the donors: “The numbers & frequencies inversely correlated with the period after the vaccination until delivery, indicating that factors causing these damages are maintained over the gestation period.”


    Troubling, it would appear that both SARS-CoV-2 infection and COVID-19 vaccination “interferes with the fate of CD34+ cells” as well as with the “hematopoietic abilities, phenotype, and survivability of populations thereof, which could result in a shortage of available CD34+ HSPCs from cord blood banking, processing for use towards HSPC-based therapies, as well as unpredictable hematological issues in HSPC recipients.”


    What’s behind this observation?

    The authors point out that “it is not completely understood why UCB CD34+ cells were becoming apoptotic.” They report that “no or undetectable levels of free S proteins nor N antigens (data now shown) in the UCB plasma were observed, indicating that there were no or undetectable levels of SARS-CoV-2 viruses or free S proteins derived from the vaccine or the viral infection interfering with CD34+HSPCs’ differentiation and survivability.”


    What’s the implication for IFN-y-dependent signaling pathways?

    The “transcriptome assay” suggests involvement of IFN-y-dependent signaling pathways which is represented by “changes in expressions of HLA-class II genes—expression of these is controlled by the HLA-class II transactivator gene (CIITA).


    The study authors report, “Our transcriptome data indicated significant decreases of some HLA class II expressions (HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, and HLA-DRB5) in purified CD34+ cells from UCB donors in the double positive, non-vaccinated group.”


    The authors point out one report that the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 “significantly increases the levels of the vaccinated subjects more than the infected subjects.”


    What’s a potential driver for decrease in UCB CD34+ cells?

    Those obtained from the double positive donor groups suggest “continuous stimulation of them by IFN-y over the course of gestation locally, such as in the feral liver, bone marrow, or the fetal spleen before circulating in the UCB.”


    What’s the possible conditions that could lead to adverse impact on the newborn immune system?

    The authors point to some evidence for decrease as well as “stress-induced differentiation of CD34+ HSPCs observed attributes to decreased circulating peripheral lymphocytes in fetuses” results in lower mononuclear cell numbers in the UCB.


    Are there any breakthroughs as to how CD34+ cell damage may impact the immune system of newborns?

    Not currently—it’s unknown. But this is important—relevant for “fighting other pathogenic viruses, bacterial infections or cancerous cells in addition to maintaining homeostatic hematopoiesis, proper humoral and cellular immunities.”


    What’s a primary concern?

    The primary concern is that the “quantitative and qualitative changes in CD34+ HSPCs of UCB induced by COVID-19 vaccines for example “might be impactful on the usage of these cells for therapeutic purposes.”


    The authors raise concern regarding other “major vaccines, such as influenza vaccines as well as bacterial pneumonia” which might “induce IFN-y release,” however, impacts are “currently unknown.”


    Limitations

    The authors report material limitations to this study. For example, they have “only studied levels of human blood cell reconstitution in peripheral blood,” representing a limitation for deeper understanding of infection or vaccination on CD34+ HSPCs.


    Also limited numbers of CD34+ cells in the UCB of the vaccinated donor group represents the biggest obstacle, particularly when considering the hematopoiesis differentiation assays, transcriptomics as the single cell level and statistical analyses.”


    The use of humanized mouse models in the quest to investigate hematopoietic ability of human CD34+ cells offer benefits but also costs, as it doesn’t support a holistic human hematopoietic environment for fully intact human blood cell reconstitution.


    What to study next?

    The authors point out the need for “prolonged follow-up studies as well as studies involving “human blood analysis in the bone marrow and lymphoid organs.” Such studies would help offer the understanding of impacts.


    The authors point out that employing “freshly isolated MNCs for humanization” after depletion of incoming T cells via anti-CD3 antibodies or pre-expanding CD34+ cells ex vivo is necessary to investigate the impact of COVID-19 vaccination on UCB CD34+ cells plus hematopoiesis in future studies.


    Finally, the authors declare to the reader that “detailed studies, such as a prolonged following up of blood phenotypes in donors delivered from mothers with SARS-CoV-2 infection or COVID-19 vaccination history over the course of patient growth, would be required to fully understand the impacts of the infection or the vaccination on their CD34+ HSPCs.”


    Funding

    NIH grants helped support this study.


    Lead Research/Investigator



    Masakazu Kamata, PhD Associate Professor; Dr. Kamata is a scientist at UAB Immunology Institute, School of Medicine; UWIRC Microbiome Center, O’Neal Comprehensive Cancer Center; Center for AIDS Research and the Inflammation, Immunology and Immunotherapies, O’Neal Comprehensive Cancer Center among other departments.


    Other authors can be reviewed at the source.


    Citation: Estep, B.K., Kuhlmann, C.J., Osuka, S., Suryavanshi, G.W., NagaokaKamata, Y., Samuel, C.N., Blucas, M.T., Jepson, C.E., Goepfert, P.A., Kamata, M., Skewed Fate and Hematopoiesis of CD34+ HSPCs in Umbilical Cord Blood Amid the COVID-19 Pandemic, ISCIENCE (2022), doi: https://doi.org/10.1016/j.isci.2022.105544.


    Importantly, the study has not been peer reviewed as of yet so should not be cited as evidence.


    References

    Skewed Fate and Hematopoiesis of CD34+ HSPCs in Umbilical Cord Blood Amid the COVID-19 Pandemic
    Umbilical cord blood (UCB) is an irreplaceable source for hematopoietic stem progenitor cells (HSPCs). However, the effects of SARS-CoV-2 infection an…
    linkinghub.elsevier.com

  • How Pfizer and Moderna used Weber Shandwick to Push Vaccines on the CDC, Corporate America, Social Media, and Medical Boards

    Billion Dollar Unit of Interpublic Group Network Committed Syndicated Fraud for Big Pharma

    How Pfizer and Moderna used Weber Shandwick to Push Vaccines on the CDC, Corporate America, Social Media, and Medical Boards
    Billion Dollar Unit of Interpublic Group Network Committed Syndicated Fraud for Big Pharma
    petermcculloughmd.substack.com


    By Peter A. McCullough, MD, MPH


    Weber Shandwick is a billion-dollar public relations and marketing firm and a subsidiary of IPG, a massive corporate conglomerate. Pfizer has used Weber Shandwick as a longstanding PR vendor for a variety of pharmaceutical and vaccine products. In 2020, Weber Shandwick began PR and marketing activities for Moderna. This was around the time the marketing firm was awarded a federal contract from the CDC. Recently Weber Shandwick was caught secretly operating an embedded marketing unit within the CDC National Center for Immunization and Respiratory Diseases and this was called out by a letter from Senator Rand Paul on October 24, 2022.

  • External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • Massachusetts Officials Refuse to Say Who Authorized Illegal COVID-19 Spyware

    Massachusetts Officials Refuse to Say Who Authorized Illegal COVID-19 Spyware - The Maine Wire
    Spyware found on New Englanders' phones raises questions about who in Mass. Gov. Charlie Baker's administration authorized the intrusion.
    www.themainewire.com


    Massachusetts Gov. Charlie Baker and Dept. of Public Health Commissioner Margret R. Cooke are refusing to say who authorized the illegal installation of COVID-19 “Mass Notify” spyware on the smartphones of potentially millions of individuals who lived in or traveled through the Commonwealth of Massachusetts.


    The revelation that Massachusetts authorities partnered with Google to install contact tracing spyware on Android devices without the permission or knowledge of users came to light as the result of a class action lawsuit filed against DPH on Nov. 14 in U.S. District Court.


    Plaintiffs Robert Wright and Johnny Kula are suing the Mass. Department of Public Health (DPH) along with Cooke in a lawsuit that alleges numerous violations of New Englanders’ constitutional rights as well as a violation of the Computer Fraud and Abuse Act.

  • Massachusetts Gov. Charlie Baker and Dept. of Public Health Commissioner Margret R. Cooke are refusing to say who authorized the illegal installation of COVID-19 “Mass Notify” spyware on the smartphones of potentially millions of individuals who lived in or traveled through the Commonwealth of Massachusetts.

    Every mobile phone is a transponder. If you pay more to get GPS inside, its a perfect personal tracker. NSA tracks all active phones at any point in time. Without GPS the phone is tracked by antenna¨ triangulation that is about 10..150 meters exact.


    But NSA also hacks bluetooth and may access your phone over the neighbors phone that has GPS...So always deactivate bluetooth/wifi and believe the system does it...

  • External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • Media finally catching up. They can't lie anymore. The data is in and it's disturbing !


    Covid is no longer mainly a pandemic of the unvaccinated. Here’s why.

    https://www.washingtonpost.com/politics/2022/11/23/vaccinated-people-now-make-up-majority-covid-deaths/


    For the first time, a majority of Americans dying from the coronavirus received at least the primary series of the vaccine.


    Fifty-eight percent of coronavirus deaths in August were people who were vaccinated or boosted, according to an analysis conducted for The Health 202 by Cynthia Cox, vice president at the Kaiser Family Foundation.


    It’s a continuation of a troubling trend that has emerged over the past year. As vaccination rates have increased and new variants appeared, the share of deaths of people who were vaccinated has been steadily rising. In September 2021, vaccinated people made up just 23 percent of coronavirus fatalities. In January and February this year, it was up to 42 percent, per our colleagues Fenit Nirappil and Dan Keating.

  • In September 2021, vaccinated people made up just 23 percent of coronavirus fatalities. In January and February this year, it was up to 42 percent, per our colleagues Fenit Nirappil and Dan Keating.

    This 23% is a myth as we know from UK since more than one year. May be now its in reality also 90% from vaccinated and they can no longer cheat it away.


    But may be USA is different people die from fear...



    90% due to the fact that this is the vaccination rate of age >65 in most countries...

  • Did they all die from or with Covid? Would be interesting to see if there is an "abnormal" higher death rate in that age group compared to pre-Corona years... here in Germany somehow not possible to find reliable data...

  • Once more the Swiss statistics page that shows a high excess death rate for age > 64

    Mortality monitoring (MOMO)
    The FSO's mortality monitoring system is designed to detect whether the weekly number of deaths is higher than expected at that time of year. Mortality rates…
    www.experimental.bfs.admin.ch


    Depending on region its between 5..30%. For most 10..15%.


    On the other side only very few people are in ICU due to CoV-19 and all have at least two risk factors.


    In USA > 1/3 of the population is pre-diabetic. 90% have no real high end medicare coverage. Thus we can't compare. But expectation of live has dropped by 3 years in USA!!!! during the pandemic...


    But real Covid data is again more manipulated here in CH. They changed the dashboard and relaxed the reporting rules...So we also here have to use the overall data that shows how bad things really are.

  • In Another “1984” Moment, FDA Tells Judge It Never Told Anyone To Not Use Ivermectin For COVID

    In Another “1984” Moment, FDA Tells Judge It Never Told Anyone To Not Use Ivermectin For COVID
    The Biden administration’s gaslighting machine is back in motion. Federal lawyers recently argued in a Texas courtroom — and apparently with straight
    www.tampafp.com


    The Biden administration’s gaslighting machine is back in motion.


    Federal lawyers recently argued in a Texas courtroom — and apparently with straight faces — that the government’s war on ivermectin during the COVID-19 pandemic was a figment of your imagination, the Epoch Times reported on Monday.

    At issue is a lawsuit brought by three doctors against the U.S. Food and Drug Administration. The doctors maintain that the FDA wrongfully interfered with their ability to treat their patients with claims that ivermectin was useless to stop or cure COVID.


    Yet during a hearing earlier this month, the Times noted, the Biden administration’s lawyers maintained the agency’s rejection of Ivermectin was simply a “recommendation.”


    U.S. Lawyers Claim Ivermectin was never prohibited for treating COVID-19. FDA merely recommended not using it.

    U.S. Lawyers Claim Ivermectin was never prohibited for treating COVID-19. FDA merely recommended not using it.
    No legal prohibition authorized or justified hospitals to withhold the drug from dying patients. Let the lawsuits begin.
    petermcculloughmd.substack.com

  • Did they all die from or with Covid? Would be interesting to see if there is an "abnormal" higher death rate in that age group compared to pre-Corona years... here in Germany somehow not possible to find reliable data...

    Yes, unfortunatley there is, maybe you check here:

    External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.


    around 01:13:00 Dr. Beck explains statistics behind Swiss mortality rates.


    i.e. very irritating highest decrease of Swiss birth rates since WWI, 9 months after vaccination in Switzerland started.


    Quite interesting and IMO alarming, my assumption is situation is not very different in DE or AT.

  • But real Covid data is again more manipulated here in CH. They changed the dashboard and relaxed the reporting rules...So we also here have to use the overall data that shows how bad things really are.

    @Jürg, your argument is supported here by Dr. BECK. 01:18:00


    External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.


    Obviously the prediction model for excess deaths in Switzerland has been changed starting at 1.1.2022.

  • Challenges with Pfizer’s Paxlovid—Does the Antiviral Actually Blunt the Development of Antiviral Adaptive Immune Responses Against COVID-19?Challenges with Pfizer’s Paxlovid—Does the Antiviral Actually Blunt the Development of Antiviral Adaptive Immune Responses Against COVID-19?

    Challenges with Pfizer’s Paxlovid—Does the Antiviral Actually Blunt the Development of Antiviral Adaptive Immune Responses Against COVID-19?
    Yet another study result in preprint involves the COVID-19 antiviral Paxlovid. The Italy-based researchers tested Nirmatrelvir in humanized mice. Paxlovid has…
    www.trialsitenews.com


    Yet another study result in preprint involves the COVID-19 antiviral Paxlovid. The Italy-based researchers tested Nirmatrelvir in humanized mice. Paxlovid has two ingredients, making it an antiviral cocktail—Nirmatrelvir being the active ingredient, and Ritonavir, the second ingredient, is only added to slow the metabolism and increase the effective dosage/half-life of Paxlovid. In the study, this was catered for with a high mouse equivalent dose administered every 12 hrs. They started treatment after 4hrs post-infection. The virus didn't have much time to replicate. Therefore, it never stimulated the adaptive arm, so the mice didn't generate cellular immunity of B Cells (which produce antibodies) or T cells. It's been shown in other studies that more severe cases of Covid elicit greater antibody response so these findings are in line with what would be expected.


    The researchers, led by corresponding authors affiliated with IRCCS Hospital San Raffaele, Scientific Research, concluded that nirmatrelvir administration early after infection blunts the development of SARS-CoV-2-specific antibody and T cell responses. Accordingly, upon secondary challenge, nirmatrelvir-treated mice recruited significantly fewer memory T and B cells to the infected lungs and to mediastinal lymph nodes, respectively.


    Together, the data highlight a potential negative impact of nirmatrelvir treatment with important implications for clinical management and might help explain the virological and/or symptomatic relapse after treatment completion reported in some individuals.


    Paxlovid is mainly being used in high-risk individuals per the Emergency Use Authorization. One qualification for a high-risk individual is that they are unvaccinated. If a person was unvaccinated and not previously infected, they would be considered to be at a high-risk for disease progression and would be more likely to be offered Paxlovid treatment. However, after an infection and treatment with Paxlovid, most patients would assume that they now have protective natural immunity.


    This study shows that due to their Paxlovid treatment their recovered immunity protection level is significantly below what natural immunity would typically confer. Therefore, it's probably prudent for any infections that were treated with Paxlovid to be considered a non-event in relation to immune protection.


    Lead Research/Investigator

    Luca G. Guidotti, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University


    Matteo Innacone, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University; Experimental Imaging Centre, IRCCS San Raffaele Scientific Institute


    Paul Elkins tracked and authored this important study led by prominent researchers in Milan, in the northern region of Italy. As the study is in preprint, it shouldn’t be cited as conclusive evidence until peer-reviewed.

  • External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • Severe COVID-19 associated with an imbalance in key immune system signaling pathway

    Severe COVID-19 associated with an imbalance in key immune system signaling pathway
    Researchers at the University of São Paulo in Brazil have found that severe COVID-19 is associated with an imbalance in an important immune system signaling…
    www.news-medical.net


    Researchers at the University of São Paulo (USP) in Brazil have found that severe COVID-19 is associated with an imbalance in an important immune system signaling pathway. The discovery helps explain at the molecular level why some people infected by SARS-CoV-2 develop a potentially fatal systemic inflammation. It also paves the way to the development of more specific therapies.


    An article on the study, which was funded by FAPESP, is published in Frontiers in Immunology.


    The researchers detected dysregulation of the immune system mediated by ATP (adenosine triphosphate), one of the main sources of energy for cellular processes. Severe COVID-19 patients had higher levels of ATP in their blood and lower levels of adenosine, which should increase when ATP is metabolized for energy production.


    Comparative study on beneficial effects of vitamins B and D in attenuating doxorubicin induced cardiotoxicity in rats: Emphasis on calcium homeostasis

    Comparative study on beneficial effects of vitamins B and D in attenuating doxorubicin induced cardiotoxicity in rats: Emphasis on calcium homeostasis
    The use of doxorubicin (DOX) to treat various tumors is limited by its cardiotoxicity. This study aimed to investigate and compare the cardioprotectiv…
    www.sciencedirect.com


    Highlights

    DOX intoxication disrupts mitochondrial structure and depletes cardiac ATP content.


    ATP depletion resulting in intense cytosolic & mitochondrial Ca2+ overload.


    Ca2+ overload activates CPN1 & CAMKII-δ provoking inflammation and apoptosis.


    NAM and 1α(OH)D3 protect against DOX-cardiomyopathy via restoring Ca2+ homeostasis.


    NAM outperformed 1α(OH)D3 in terms of cardioprotection.


    Calcium and ATP control multiple vital functions

    https://royalsocietypublishing.org/doi/10.1098/rstb.2015.0418